Genomics Competitors

Stocks . Taiwan . 
Stock . Genomics BioSci Tech
4195 Stock  TWD 24.80  0.25  1.02%   
Genomics BioSci Tech competes with Chunghwa Chemical, Enimmune Corporation, GeneReach Biotechnology, and GlycoNex; as well as few others. The company operates under Healthcare sector and is part of Biotechnology industry. Analyzing Genomics BioSci competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Genomics BioSci to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Genomics BioSci Correlation with its peers.

Genomics BioSci vs GlycoNex Correlation

Modest diversification

The correlation between Genomics BioSci Tech and 4168 is 0.29 (i.e., Modest diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Genomics BioSci Tech and 4168 in the same portfolio, assuming nothing else is changed.

Moving against Genomics Stock

  0.566547 Medigen Vaccine BiologicsPairCorr
  0.534162 PharmaEnginePairCorr
  0.466712 Ever Supreme BioPairCorr
  0.444174 OBI Pharma SplitPairCorr
  0.362538 Kee Tai PropertiesPairCorr
Hype
Prediction
LowEstimatedHigh
22.8524.8026.75
Details
Intrinsic
Valuation
LowRealHigh
21.0022.9524.90
Details
Naive
Forecast
LowNextHigh
22.4324.3826.32
Details
Bollinger
Band Projection (param)
LowerMiddle BandUpper
24.1725.4326.70
Details

Genomics BioSci Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Genomics BioSci and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Genomics and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Genomics BioSci Tech does not affect the price movement of the other competitor.

High positive correlations

4171
+ 0.71
6709
4171
+ 0.62
1762
6934
+ 0.59
6676
1762
+ 0.47
6676
6872
+ 0.46
6709
4171
+ 0.46
6872
  

High negative correlations

6934
- 0.61
4724
4168
- 0.6
6709
4724
- 0.3
1762
4168
- 0.28
6846
4724
- 0.25
6676
4171
- 0.21
4724

Risk-Adjusted Indicators

There is a big difference between Genomics Stock performing well and Genomics BioSci Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Genomics BioSci's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
6676  2.14  0.30  0.10  1.61  2.05 
(2.94)
 5.26 
(4.47)
 22.10 
1762  0.58 (0.04) 0.00 (0.12) 0.00 
 0.00 
 1.41 
(1.16)
 4.75 
6709  1.66 (0.29) 0.00  0.82  0.00 
 0.00 
 3.20 
(3.71)
 16.90 
6846  0.74  0.02 (0.05) 0.24  0.90 
(1.01)
 1.91 
(1.71)
 5.90 
6872  0.96 (0.07) 0.00 (0.08) 0.00 
 0.00 
 2.32 
(1.91)
 6.77 
6564  1.37  0.07  0.01  0.32  1.31 
(1.88)
 4.78 
(2.33)
 9.31 
4724  1.32 (0.06) 0.00 (0.17) 0.00 
 0.00 
 5.26 
(3.72)
 14.75 
6934  4.65  2.23  0.40 (2.51) 2.98 
(5.54)
 18.06 
(8.04)
 45.51 
4171  2.30  0.03  0.00  0.05  0.00 
 0.00 
 9.86 
(5.17)
 19.32 
4168  1.82  0.36  0.13  19.28  1.91 
(2.29)
 7.23 
(2.70)
 18.02 

Genomics BioSci Competitive Analysis

The better you understand Genomics BioSci competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Genomics BioSci's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Genomics BioSci's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
4195 6676 1762 6709 6846 6872 6564 4724 6934 4171
 1.02 
 24.80 
Genomics
 2.24 
 15.30 
Sunny
 0.19 
 25.85 
Chunghwa
 7.18 
 28.35 
Advagene
 0.81 
 74.50 
Greenyn
 0.25 
 20.25 
NaviFUS
 0.48 
 20.75 
Enimmune
 0.32 
 15.45 
Meribank
 3.88 
 148.50 
6934
 2.08 
 21.15 
GeneReach
Market Volatility
(90 Days Market Risk)
Very steady
Not too volatile
Very steady
Not too volatile
Very steady
Very steady
Very steady
Not too volatile
Very steady
Not too volatile
Market Performance
(90 Days Performance)
Weakest
Fair
Weakest
Weakest
Weak
Weakest
Soft
Weakest
Solid
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Low
Unknown
Low
Fair
Unknown
Unknown
High
Unknown
Unknown
Low
Current Valuation
(Equity Enterprise Value)
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Sell
Cautious Hold
Hold
Strong Sell
Sell
Hold
Cautious Hold
Sell
Strong Sell
Strong Sell
Current Ratio
3.01
N/A
1.36
N/A
N/A
N/A
15.1
N/A
N/A
5.21
Net Asset
N/A
N/A
4.38 B
N/A
N/A
N/A
N/A
N/A
N/A
1.68 B
Profit Margin
N/A
N/A
0.23
N/A
N/A
N/A
-81.58
N/A
N/A
0.38
EBITDA
25.55 M
N/A
632.93 M
N/A
N/A
N/A
(66.03 M)
N/A
N/A
535.64 M
Operating Margin
N/A
N/A
0.22
N/A
N/A
N/A
-101.32
N/A
N/A
0.43
Current Valuation
N/A
N/A
5.19 B
N/A
N/A
N/A
1.94 B
N/A
N/A
2.09 B
Price To Book
N/A
N/A
1.56
N/A
N/A
N/A
3.96
N/A
N/A
2.37
Retained Earnings
N/A
N/A
630 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
N/A
729 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Five Year Return
N/A
N/A
2.83
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Beta
0.64
N/A
0.86
N/A
N/A
N/A
0.37
N/A
N/A
0.63
Number Of Employees
16
N/A
21
10
N/A
N/A
27
N/A
N/A
16
Shares Outstanding
N/A
N/A
77.56 M
N/A
N/A
N/A
60 M
N/A
N/A
45.97 M
Cash Flow From Operations
40.87 M
N/A
219.18 M
N/A
N/A
N/A
(114.54 M)
N/A
N/A
348.99 M
Annual Yield
N/A
N/A
0.0198
N/A
N/A
N/A
N/A
N/A
N/A
0.0835
Total Debt
86.52 M
N/A
600 M
N/A
N/A
N/A
7.97 M
N/A
N/A
217.39 M
Return On Equity
N/A
N/A
0.17
N/A
N/A
N/A
-9.41
N/A
N/A
0.3
Z Score
9.0
N/A
4.8
N/A
N/A
N/A
N/A
N/A
N/A
7.2
Book Value Per Share
12.89
N/A
39.98
N/A
N/A
N/A
10.29
N/A
N/A
24.36
Return On Asset
N/A
N/A
0.066
N/A
N/A
N/A
-6.93
N/A
N/A
0.13
Current Liabilities
N/A
N/A
617 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
N/A
N/A
4.38 B
N/A
N/A
N/A
N/A
N/A
N/A
1.68 B
Debt To Equity
0.11
N/A
41.0
N/A
N/A
N/A
0.013
N/A
N/A
0.3
Last Dividend Paid
1.17
N/A
1.3
N/A
N/A
N/A
N/A
N/A
N/A
4.55
Target Price
N/A
N/A
125.0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Shares Owned By Institutions
N/A
N/A
4.61
N/A
N/A
N/A
N/A
N/A
N/A
4.57
Market Capitalization
1.34 B
N/A
5.17 B
879.46 M
N/A
N/A
2.44 B
N/A
N/A
2.73 B
Price To Earning
26.25
N/A
9.2
N/A
N/A
N/A
N/A
N/A
N/A
8.39
Price To Sales
N/A
N/A
2.37
N/A
N/A
N/A
33.44
N/A
N/A
2.88
Net Income
45.34 M
N/A
400.78 M
N/A
N/A
N/A
(59.64 M)
N/A
N/A
376.62 M
Earnings Per Share
0.72
N/A
6.21
N/A
N/A
N/A
-1.4
N/A
N/A
6.9
Shares Owned By Insiders
N/A
N/A
39.75
N/A
N/A
N/A
N/A
N/A
N/A
34.96
Revenue
N/A
N/A
1.93 B
N/A
N/A
N/A
73.11 M
N/A
N/A
1.01 B
Working Capital
N/A
N/A
112 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
110.98 M
N/A
97.43 M
N/A
N/A
N/A
390.32 M
N/A
N/A
811.4 M
Cash Per Share
1.76
N/A
1.26
N/A
N/A
N/A
6.51
N/A
N/A
17.65
Gross Profit
N/A
N/A
949.39 M
N/A
N/A
N/A
8.22 M
N/A
N/A
746.98 M
Day Typical Price
24.67
15.58
25.8
28.33
74.33
20.22
20.7
15.25
151.5
21.08
Accumulation Distribution
0.032
0.0586
0.0173
0.0123
0.0067
0.0196
0.0263
0.0388
0.0935
0.0327
Market Facilitation Index
0.8
0.95
0.45
0.35
0.5
0.4
0.55
0.6
15.0
0.7
Daily Balance Of Power
0.3125
(0.37)
(0.11)
5.428571
1.2
0.125
(0.18)
(0.08)
(0.40)
(0.64)
Period Momentum Indicator
0.25
(0.35)
(0.05)
1.9
0.6
0.05
(0.10)
(0.05)
(6.00)
(0.45)
Rate Of Daily Change
1.01
0.98
1.0
1.07
1.01
1.0
1.0
1.0
0.96
0.98
Day Median Price
24.6
15.73
25.78
28.33
74.25
20.2
20.67
15.15
153.0
21.05
Price Action Indicator
0.33
(0.60)
0.05
0.98
0.55
0.075
0.025
0.27
(7.50)
(0.13)
Relative Strength Index
45.83
N/A
58.48
49.51
52.12
47.86
N/A
N/A
N/A
52.29
Coefficient Of Variation
(1,337)
1111.58
(4,945)
(838.21)
3429.85
(5,383)
1940.15
(7,463)
343.99
(6,971)
Mean Deviation
1.38
2.14
0.5842
1.66
0.7358
0.957
1.37
1.32
4.65
2.3
Jensen Alpha
(0.17)
0.301
(0.04)
(0.29)
0.015
(0.07)
0.0702
(0.06)
2.23
0.0294
Total Risk Alpha
(0.34)
(0.02)
(0.11)
(0.57)
(0.08)
(0.16)
(0.09)
(0.26)
1.47
(0.40)
Sortino Ratio
N/A
0.0955
N/A
N/A
(0.05)
N/A
0.0146
N/A
0.4019
N/A
Downside Variance
N/A
6.63
N/A
N/A
1.1
N/A
2.09
N/A
27.47
N/A
Standard Deviation
1.95
3.61
0.8602
2.61
1.06
1.36
1.93
2.34
7.52
3.59
Kurtosis
1.49
13.24
4.18
8.53
1.67
2.88
4.07
8.18
9.39
2.65
Potential Upside
3.8
5.26
1.41
3.2
1.91
2.32
4.78
5.26
18.06
9.86
Treynor Ratio
(0.89)
1.61
(0.12)
0.8206
0.2429
(0.08)
0.3178
(0.17)
(2.51)
0.0462
Maximum Drawdown
8.92
22.1
4.75
16.9
5.9
6.77
9.31
14.75
45.51
19.32
Variance
3.79
13.0
0.7399
6.82
1.12
1.85
3.72
5.49
56.48
12.91
Market Risk Adjusted Performance
(0.88)
1.62
(0.11)
0.8306
0.2529
(0.07)
0.3278
(0.16)
(2.50)
0.0562
Risk Adjusted Performance
(0.05)
0.0738
(0.01)
(0.08)
0.0244
(0.01)
0.0439
(0)
0.2219
(0)
Skewness
0.2872
2.91
1.34
1.89
(0.02)
1.25
1.52
1.99
2.41
0.9853
Semi Deviation
N/A
2.05
N/A
N/A
0.9006
N/A
1.31
N/A
2.98
N/A
Information Ratio
(0.12)
0.0682
(0.11)
(0.15)
(0.04)
(0.08)
0.0109
(0.05)
0.2803
(0.04)
Value At Risk
(3.21)
(4.47)
(1.16)
(3.71)
(1.71)
(1.91)
(2.33)
(3.72)
(8.04)
(5.17)
Expected Short fall
N/A
(2.94)
N/A
N/A
(1.01)
N/A
(1.88)
N/A
(5.54)
N/A
Downside Deviation
N/A
2.58
N/A
N/A
1.05
N/A
1.45
N/A
5.24
N/A
Semi Variance
N/A
4.18
N/A
N/A
0.8111
N/A
1.72
N/A
8.86
N/A

Genomics BioSci Competition Performance Charts

Five steps to successful analysis of Genomics BioSci Competition

Genomics BioSci's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Genomics BioSci Tech in relation to its competition. Genomics BioSci's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Genomics BioSci in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Genomics BioSci's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Genomics BioSci Tech, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Genomics BioSci position

In addition to having Genomics BioSci in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run Broad Market ETFs Thematic Idea Now

Broad Market ETFs
Broad Market ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Broad Market ETFs theme has 105 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Broad Market ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Genomics Stock Analysis

When running Genomics BioSci's price analysis, check to measure Genomics BioSci's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Genomics BioSci is operating at the current time. Most of Genomics BioSci's value examination focuses on studying past and present price action to predict the probability of Genomics BioSci's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Genomics BioSci's price. Additionally, you may evaluate how the addition of Genomics BioSci to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY